However, after 24 weeks of treatment, JKB-121 was found to not be superior to the placebo in reducing serum ALT or liver fat accumulation (measured with magnetic resonance imaging), and further studies are needed to address the role of TLR4 antagonists in the treatment of NAFLD. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.